Bristol-Myers Squibb Company

Hawaii Secures $700 Million Settlement from Bristol Myers Squibb and Sanofi Over Plavix Efficacy in Diverse Populations

12 days ago

• Hawaii will receive $700 million from Bristol Myers Squibb and Sanofi following litigation over blood thinner Plavix's reduced efficacy in Asian American, Pacific Islander, and Native Hawaiian populations. • The settlement resolves a 13-year legal battle where the state accused the pharmaceutical companies of failing to warn that Plavix could be ineffective in certain ethnic groups, with the medication prescribed over 837,000 times in Hawaii between 1998-2010. • The case highlights critical concerns about pharmaceutical companies' consideration of ethnic and genetic diversity in drug development, potentially setting precedent for similar cases in jurisdictions with diverse populations.